The Challenge Non-Typhoidal <i>Salmonella</i> (CHANTS) Consortium: Development of a non-typhoidal <i>Salmonella</i> controlled human infection model: Report from a consultation group workshop, 05 July 2022, London, UK.



Smith, Christopher ORCID: 0000-0001-7369-2034, Smith, Emma, Chiu, Christopher ORCID: 0000-0003-0914-920X, Hinton, Jay, Perez Sepulveda, Blanca ORCID: 0000-0002-2891-4010, Gordon, Melita ORCID: 0000-0002-0629-0884, Choy, Robert KM, Hill, Peter WS, Meiring, James E, Darton, Thomas C ORCID: 0000-0003-2209-9956
et al (show 4 more authors) (2023) The Challenge Non-Typhoidal <i>Salmonella</i> (CHANTS) Consortium: Development of a non-typhoidal <i>Salmonella</i> controlled human infection model: Report from a consultation group workshop, 05 July 2022, London, UK. Wellcome open research, 8. 111-.

[img] Text
The Challenge Non-Typhoidal iSalmonellai (CHANTS) Consortium Development of a non-typhoidal iSalmonellai controlled human in.pdf - Open Access published version

Download (742kB) | Preview

Abstract

Invasive non-typhoidal <i>Salmonella</i> disease (iNTS) is a major cause of morbidity and mortality globally, particularly as a cause of bloodstream infection in children and immunocompromised adults in sub-Saharan Africa. Vaccines to prevent non-typhoidal <i>Salmonella</i> (NTS) would represent a valuable public health tool in this setting to avert cases and prevent expansion of antimicrobial resistance. Several NTS and combination typhoidal-NTS vaccine candidates are in early-stage development, although the pathway to licensure is unclear due to challenges in conducting large phase III field trials. Controlled human infection models (CHIM) present an opportunity to accelerate vaccine development for a range of enteric pathogens. Several recent typhoidal <i>Salmonella</i> CHIMs have been conducted safely and have played pivotal roles in progressing vaccine candidates to pre-qualification and licensure. The Challenge Non-Typhoidal <i>Salmonella</i> (CHANTS) consortium has been formed with funding from the Wellcome Trust, to deliver the first NTS CHIM, which can act as a platform for future vaccine evaluation. This paper reports the conclusions of a consultation group workshop convened with key stakeholders. The aims of this meeting were to: (1) define the rationale for an NTS CHIM (2) map the NTS vaccine pipeline (3) refine study design and (4) establish potential future use cases.

Item Type: Article
Uncontrolled Keywords: CHANTS Consortium
Divisions: Faculty of Health and Life Sciences
Faculty of Health and Life Sciences > Institute of Infection, Veterinary and Ecological Sciences
Depositing User: Symplectic Admin
Date Deposited: 16 Jan 2024 11:12
Last Modified: 16 Jan 2024 12:09
DOI: 10.12688/wellcomeopenres.19012.2
URI: https://livrepository.liverpool.ac.uk/id/eprint/3177866